Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of PBFT02 in Frontotemporal Dementia with GRN or C9orf72 Mutations
2023-507724-23-00Phase 2Completed
- Sponsor
- Passage Bio
- Start
- Feb 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 5
01
Overview
Phase 2, single-arm trial of PBFT02 in frontotemporal dementia (FTD), sponsored by Passage Bio. Primary endpoints: Safety and tolerability of PBFT02 and Pharmacodynamics of PBFT02. Started Feb 2024; status: completed.
02
Drugs
PBFT02
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2023-507724-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507724-23-00.